Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Ovarian disrupting effects of per-and polyfluoroalkyl substances (PFAS) on gonadotropin-dependent folliculogenesis and ovulation

Award Number: R01ES035766
ORGANIZATION: NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 12/13/2024
PERIOD OF PERFORMANCE END DATE: 10/31/2029

Group Awards By:

View Award Description

Ovarian disrupting effects of per-and polyfluoroalkyl substances (PFAS) on gonadotropin-dependent folliculogenesis and ovulation - PROJECT SUMMARY The per- and polyfluoroalkyl substances (PFAS) are human-made organic compounds that are widely used in consumer and industrial products. The strong C-F bonds of PFAS make them highly resistant to environmental degradation and thus earn PFAS the name “Forever Chemicals. Humans can be exposed to high levels of PFAS through drinking water and foods in areas near the contaminated sites. PFAS are rarely metabolized once absorbed, with half-lives as long as 8-9 years. Epidemiological evidence revealed associations between PFAS and female ovarian disorders, such as premature ovarian failure (POF), irregular menstrual cycles, and infertility, but the underlying mechanisms remain elusive. So far, nearly all studies focused on perfluorooctanoic acid (PFOA) and perfluorooctane sulfonate (PFOS), two long-chain legacy PFAS that have been phased out. The ovarian toxicity (ovotoxicity) of other widely used long-chain PFAS such as perfluorononanoic acid (PFNA) are rarely studied, despite some may have similar or even higher contamination levels. In the real world, humans are exposed to PFAS mixtures, but their ovarian impacts are poorly characterized. Our recently published studies and preliminary data support ovotoxicity of PFAS. (1) A cross-sectional epidemiological analysis of the NHANES dataset revealed positive associations between serum concentrations of long-chain PFAS and long-term amenorrhea in women of reproductive age; (2) In an in vivo mouse exposure model, PFNA accumulated in the ovary to levels observed in women, and PFNA dose-dependently inhibited ovulation; (3) In an in vitro mouse ovarian follicle culture system, PFNA concentration-dependently inhibited follicle maturation and ovulation; and (4) A selective antagonist of peroxisome proliferator-activated receptor gamma (PPARγ) rescued PFNA-blocked ovulation in both in vitro and in vivo models. With these findings, we will test our central hypothesis that: (1) at environmentally high but human-relevant exposure levels, PFNA acts primarily as a PPARγ agonist, as the molecular initiating event (MIE), in follicular granulosa cells to interfere with folliculogenesis, leading to impaired ovarian functions and female reproduction; (2) also via PPARγ-mediated MIEs, PFAS of major public health concern and their mixtures produce similar ovotoxic effects but with different potentials. We will integrate in vivo, in vitro, and in silico models to test our hypotheses in three Specific Aims. In Aim 1, we will use a mouse model of natural ovarian cycles and human-relevant doses and duration of PFNA exposure via drinking water to investigate ovarian disrupting effects of PFNA and female reproductive outcomes. In Aim 2, we will study the mechanistic and causal roles of PPARγ in PFNA-induced ovarian follicle maturation and ovulation defects. In Aim 3, we will use experimental and computational models to determine the ovotoxicity of PFAS singles and mixtures of major health concern. This research is highly innovative and significant given the emerging concern of PFAS on female reproduction. Elucidating the ovotoxicity of PFAS will enable us to speed up the development of prevention, mitigation, and remediation methods to protect female reproductive health and fertility.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $562,342 )
2026	2026	RUTGERS THE STATE UNIVERSITY OF NEW JERSEY	65 BERGEN ST	NEWARK	NJ	07107	ESSEX	USA	Environmental Health	000	2	12/12/2025	NON-COMPETING CONTINUATION	$562,342
														Subtotal = $562,342

Issue Date FY: 2025 ( Subtotal = $561,584 )
2025	2025	RUTGERS THE STATE UNIVERSITY OF NEW JERSEY	65 BERGEN ST	NEWARK	NJ	07107	ESSEX	USA	Environmental Health	001	1	9/26/2025	NEW	$0
2025	2025	RUTGERS THE STATE UNIVERSITY OF NEW JERSEY	65 BERGEN ST	NEWARK	NJ	07107	ESSEX	USA	Environmental Health	000	1	12/12/2024	NEW	$561,584
														Subtotal = $561,584

Grand Total All Awards = $1,123,926

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Ovarian disrupting effects of per-and polyfluoroalkyl substances (PFAS) on gonadotropin-dependent folliculogenesis and ovulation

Award Number: R01ES035766

ORGANIZATION: NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 12/13/2024

PERIOD OF PERFORMANCE END DATE: 10/31/2029

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer